ReNerve Limited Asian Market Update – NervAlign® Nerve Cuff
Marketing Approval in Thailand & Initial Sales in Hong Kong Highlights: • ReNerve has received marketing approval for its NervAlign®… Read more
ReNerve Receives Additional $139,537 in R&D Tax Incentive Refund
ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to announce that it has received an additional tax refund of… Read more
ReNerve releases 31 December 2024 Half Year Results
Highlights: • Strong Sales Growth: US sales increased by approximately 100% in 2024 compared to 2023. Revenue for 1H FY25… Read more
ReNerve enters partnership for NervAlign® Nerve Cuff in Mexico
Highlights: • ReNerve has entered a partnership with Imbiomex to progress the NervAlign® Nerve Cuff through regulatory approval and thereafter… Read more
ReNerve Quarterly Investor Update
Development of Novel Nerve Repair & Regeneration Products ReNerve is focused on developing a portfolio of products for the nerve… Read more
ReNerve Limited – Quarterly Activities Report for the Period Ended 31 December 2024
Highlights: • ReNerve Limited (“ReNerve” or “the Company”) commenced trading on the ASX on 26 November 2024 following a heavily… Read more
ReNerve Signs Exclusive Partnership with Established Supplier in the Middle East to Further Accelerate International Expansion
Highlights: ● ReNerve Limited has partnered with Union MediScience B.S.C in an exclusive distribution agreement for the sales and marketing… Read more
ReNerve Signs Exclusive Partnership with Leading Distributor in Hong Kong to Accelerate International Expansion
Highlights: ● ReNerve Limited has partnered with Accession Medical Supplies Co in an exclusive distribution agreement for sales and marketing… Read more
ReNerve Presentation
ReNerve is pleased to provide its latest Investor Presentation.